Authors

Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape

Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.

Assessing Bleeding Disorders: Keys for Hem/Onc Fellows

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

Education Is a Personal Mission

Santosh Saraf, MD, changed his major 3 times as an undergrad at Penn State University, bouncing from premed to mathematics to marine biology before settling back into medicine.

Reflecting on Research Highlights in Acute Leukemia and Multiple Myeloma With Drs Hildebrandt and Baljevic

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Targeting Menin: A New Frontier in Treating Refractory Leukemias

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

LAG-3 Fills a Complex Role in the Immune System

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Whole Genome Sequencing for AML/MDS Risk Stratification

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Roswell Park Team Provides First Direct Evidence of CD28 Effects on CAR T-Cell Therapy

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Zavabresib Nets FDA Orphan Drug Designation for Myelofibrosis

The FDA has granted orphan drug designation to zavabresib for the treatment of patients with myelofibrosis.

A Prayer for a More Equitable Future

Russell J. Ledet, PhD, discusses being a Black man in the field of oncology.

The Mullin Sisters

A breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.

Raising the Bar in the First-Line Treatment of EGFR+* mNSCLC Advanced Lung Cancer

Taking Back Our Empathy: Reflections on a New Model of Medical Education

Bharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Make Time for Your Own Health

Although graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.

Undocumented Immigrants With Cancer Face Unique Care Challenges

Undocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.

Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology Fellow

Tumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.

Reducing Burnout Requires an Organizational Response

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.